Lihong Wu

Dr. Lihong Wu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2022 in Molecules
Verified
Journal Article
Open access
PDF file
ZWZhengyang Wang
Zhengyang Wang
CYChunjuan Yang
Chunjuan Yang
LWLihong Wu
Lihong Wu
JSJiahui Sun
Jiahui Sun
ZWZhenyue Wang
Zhenyue Wang
ZWZhiBin Wang
ZhiBin Wang
The incidence of colon cancer is increasing year over year, seriously affecting human health and quality of life in recent years. However, traditional Chinese medicine (TCM) has been utilized for the treatment of colon cancer. S. officinalis Saponins (S-Saponins), the potential compound of TCM, displays multiple biological activities in colon cancer treatment. In our study, ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) combined with multivariate statistical analysis were performed to analyze and identify raw and processed saponins. Then, MTT and cell migration assays were used to preliminarily explore the effects of saponins in vitro on colon cancer cells. The results showed that 29 differential saponins compounds under Paozhi were identified by UHPLC-MS/MS. Moreover, in vitro validation showed that Sprocessed better inhibited the proliferation and migration of colon cancer cells than Sraw. This study provides a basis for the determination of the chemical fundamentals of the efficacy changes during Paozhi through inferring the changes in saponin components and its possible transformation mechanisms before and after processing S. officinalis. Meanwhile, it also provides new insights into potential bioactive ingredients for the treatment of colon cancer.

24 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
FWFanshu Wei
Fanshu Wei
CYChunjuan Yang
Chunjuan Yang
LWLihong Wu
Lihong Wu
JSJiahui Sun
Jiahui Sun
ZWZhenyue Wang
Zhenyue Wang
ZWZhiBin Wang
ZhiBin Wang
A selective and rapid ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC–MS/MS) method was established and validated for the determination of ziyuglycoside I, 3β,19α-dihydroxyurs-12-en-28-oic-acid 28-β-d-glucopyranosyl ester, and pomolic acid in rats after the oral administration of ziyuglycoside I, 3β,19α-dihydroxyurs-12-en-28-oic-acid 28-β-d-glucopyranosyl ester, pomolic acid, and Sanguisorba officinalis L. extract. The separation was carried out on an ACQUITY UPLC®HSS T3 column (2.1 mm × 100 mm, 1.8 μm), using methanol and 5 mmol/L ammonium acetate water as the mobile phase. The three compounds were quantified using the multiple reaction monitoring mode with the electrospray ion source in both the positive and negative mode. Liquid-liquid extraction was applied to the plasma sample preparation. Bifendate was selected as the internal standard. The intra-day and inter-day precision and the accuracy of the method were all within receivable ranges. The lower limit of quantification of ziyuglycoside I, 3β,19α-dihydroxyurs-12-en-28-oic-acid 28-β-d-glucopyranosyl ester, and pomolic acid were 6.50, 5.75, and 2.63 ng/mL, respectively. The extraction recoveries of analytes in rat plasma ranged from 83 to 94%. The three components could be rapidly absorbed into the blood (Tmax, 1.4–1.6 h) both in the single-administration group or S. officinalis extract group, but the first peak of PA occurred at 0.5 h and the second peak at 4–5 h in the S. officinalis extract. Three compounds were eliminated relatively slowly (t1/2, 7.3–11 h). The research was to establish a rapid, sensible, and sensitive UHPLC–MS/MS method using the multi-ion mode for multi-channel simultaneous mensuration pharmacokinetics parameters of three compounds in rats after oral administration of S. officinalis extract. This study found, for the first time, differences in the pharmacokinetic parameters of the three compounds in the monomer compounds and S. officinalis extract administration, which preliminarily revealed the transformation and metabolism of the three compounds in vivo.

25 March 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
MWMeng Wang
Meng Wang
XXXin-Rui Xu
Xin-Rui Xu
QBQian-Xiang Bai
Qian-Xiang Bai
LWLihong Wu
Lihong Wu
YXYang xin-peng
Yang xin-peng
HKHaixue Kuang
Haixue Kuang

30 March 2026 in Molecules
Verified
Journal Article
Open access
PDF file
JMJian-Qiang Ma
Jian-Qiang Ma
YSYanping Sun
Yanping Sun
TWTian-Yuan Wu
Tian-Yuan Wu
HYHui-Yue Yuan
Hui-Yue Yuan
XLXin-Lan Li
Xin-Lan Li
HKHaixue Kuang
Haixue Kuang
Eupatorium fortunei Turcz. (E. fortunei), a member of the Asteraceae family, is a widely utilized traditional medicinal herb in China. Historically, it has been employed to treat conditions such as influenza, nausea, anorexia, and various ailments associated with “pathogenic dampness”. To the best of our knowledge, this study presents the first systematic review of recent research on E. fortunei, based on a comprehensive literature search across both Chinese and international databases, including Web of Science, PubMed, SciFinder, and CNKI. The review encompasses its botanical characteristics, traditional applications, phytochemical composition, pharmacological properties, and toxicological profiles. Current research reveals a diverse array of phytochemicals in E. fortunei, with 162 compounds identified to date, including thymol derivatives, terpenoids, alkaloids, benzofurans, fatty acids, and other bioactive constituents. These compounds exhibit a broad spectrum of pharmacological activities, encompassing anti-cancer, anti-viral, anti-fungal, anti-inflammatory, and anti-diabetic effects. Among these, thymol derivatives and benzofurans emerge as the most prominent bioactive compounds, demonstrating potent cytotoxic effects against various tumor cell lines. Although E. fortunei is generally considered safe, certain pyrrolizidine alkaloids (PAs) present potential hepatotoxic risks, which can be mitigated through appropriate dosage control and formulation optimization. As a valuable traditional Chinese medicinal herb, E. fortunei exhibits substantial therapeutic potential. In conclusion, this review provides a comprehensive and systematic overview of current research on E. fortunei, offering scientific evidence and guidance for its rational development and clinical application.